Universität zu Köln

Metzenmacher, Martin ORCID: 0000-0001-5395-9010, Rizzo, Filippo, Kambartel, Kato, Panse, Jens, Schaufler, Diana, Scheffler, Matthias ORCID: 0000-0002-9031-1368, Azeh, Ivo, Hoiczyk, Mathias, Turki, Amin T., Atz, Judith, Buchner, Hannes, Hoffmann, Christopher and Christoph, Daniel C. (2021). Real-world efficacy of docetaxel plus nintedanib after chemo-immunotherapy failure in advanced pulmonary adenocarcinoma. Future Oncol., 17 (30). S. 3965 - 3977. LONDON: FUTURE MEDICINE LTD. ISSN 1744-8301

Full text not available from this repository.

Abstract

Lay abstract The standard of care for patients with lung adenocarcinoma has advanced with the introduction of immunotherapy in the first-line setting. However, limited clinical data are available to help guide treatment decisions after failure of chemotherapy and immunotherapy. Nintedanib is an oral antiangiogenic agent that is approved in the EU and other countries in combination with docetaxel for the treatment of patients with advanced/metastatic lung adenocarcinoma after first-line chemotherapy. This study is a retrospective, real-world analysis of docetaxel plus nintedanib in 93 patients with advanced lung adenocarcinoma who progressed on immunotherapy (either in sequence or in combination with chemotherapy). The results suggest that docetaxel plus nintedanib offers a meaningful clinical benefit in this setting. Safety findings were generally consistent with the known safety profile of docetaxel plus nintedanib. Aim: This real-world analysis evaluated docetaxel plus nintedanib in patients with advanced pulmonary adenocarcinoma after chemotherapy and immune checkpoint inhibitor failure, for whom treatment options are limited. Methods: Data were sourced retrospectively from seven German centers. Results: Of 93 patients, overall response rate was 41.4% (disease control rate: 75.9%). Of 57 patients given third-line docetaxel plus nintedanib, overall response rate was 50.0% (disease control rate: 82.7%). Median overall survival following third-line docetaxel plus nintedanib was 8.4 months. Adverse events were consistent with the known safety profile of docetaxel plus nintedanib. Conclusion: To date, this was the largest retrospective, real-world analysis of docetaxel plus nintedanib after chemotherapy-immunotherapy failure, indicating that docetaxel plus nintedanib offers meaningful clinical benefits in this setting.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Metzenmacher, Martin UNSPECIFIED orcid.org/0000-0001-5395-9010 UNSPECIFIED Rizzo, Filippo UNSPECIFIED UNSPECIFIED UNSPECIFIED Kambartel, Kato UNSPECIFIED UNSPECIFIED UNSPECIFIED Panse, Jens UNSPECIFIED UNSPECIFIED UNSPECIFIED Schaufler, Diana UNSPECIFIED UNSPECIFIED UNSPECIFIED Scheffler, Matthias UNSPECIFIED orcid.org/0000-0002-9031-1368 UNSPECIFIED Azeh, Ivo UNSPECIFIED UNSPECIFIED UNSPECIFIED Hoiczyk, Mathias UNSPECIFIED UNSPECIFIED UNSPECIFIED Turki, Amin T. UNSPECIFIED UNSPECIFIED UNSPECIFIED Atz, Judith UNSPECIFIED UNSPECIFIED UNSPECIFIED Buchner, Hannes UNSPECIFIED UNSPECIFIED UNSPECIFIED Hoffmann, Christopher UNSPECIFIED UNSPECIFIED UNSPECIFIED Christoph, Daniel C. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-599616
DOI:	10.2217/fon-2021-0424
Journal or Publication Title:	Future Oncol.
Volume:	17
Number:	30
Page Range:	S. 3965 - 3977
Date:	2021
Publisher:	FUTURE MEDICINE LTD
Place of Publication:	LONDON
ISSN:	1744-8301
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language CELL LUNG-CANCER; IMMUNE CHECKPOINT INHIBITORS; TRIPLE ANGIOKINASE INHIBITOR; CHEMOTHERAPY; RESISTANCE Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/59961